Financial reports
10-Q
2024 Q1
Quarterly report
14 May 24
ARS
2023 FY
Annual report to shareholders
26 Apr 24
10-K
2023 FY
Annual report
28 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
11 Aug 23
10-Q
2023 Q1
Quarterly report
9 May 23
ARS
2022 FY
Annual report to shareholders
1 May 23
10-K
2022 FY
Annual report
28 Mar 23
10-Q
2022 Q3
Quarterly report
15 Dec 22
Current reports
8-K
Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
14 May 24
8-K
Results of Operations and Financial Condition
24 Apr 24
8-K
Acrivon Therapeutics Announces $130 Million Private Placement Financing
9 Apr 24
8-K
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
28 Mar 24
8-K
Acrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA, Experienced Board Member and Healthcare Investor, to its Board of Directors
4 Mar 24
8-K
Acrivon Therapeutics Appoints Seasoned Industry Executive Ivana Magovčević-Liebisch, Ph.D., J.D., to Board of Directors
8 Feb 24
8-K
Regulation FD Disclosure
8 Jan 24
8-K
Entry into a Material Definitive Agreement
8 Dec 23
8-K
Acrivon Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
9 Nov 23
8-K
Regulation FD Disclosure
5 Sep 23
Registration and prospectus
S-3
Shelf registration
17 Apr 24
S-8
Registration of securities for employees
29 Mar 24
S-3
Shelf registration
1 Dec 23
S-8
Registration of securities for employees
11 Aug 23
S-8
Registration of securities for employees
29 Mar 23
S-8
Registration of securities for employees
17 Nov 22
424B4
Prospectus supplement with pricing info
16 Nov 22
S-1MEF
Registration of additional securities for an S-1
14 Nov 22
FWP
Free writing prospectus
14 Nov 22
S-1/A
IPO registration (amended)
8 Nov 22
Other
EFFECT
Notice of effectiveness
30 Apr 24
EFFECT
Notice of effectiveness
18 Dec 23
CORRESP
Correspondence with SEC
12 Dec 23
UPLOAD
Letter from SEC
5 Dec 23
EFFECT
Notice of effectiveness
10 Nov 22
SEC STAFF
SEC staff action: Order
9 Nov 22
CERT
Certification of approval for exchange listing
8 Nov 22
CORRESP
Correspondence with SEC
7 Nov 22
CORRESP
Correspondence with SEC
7 Nov 22
CORRESP
Correspondence with SEC
17 Oct 22